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Bladder cancer (BC) is the second most common genitourinary malignancy with high recurrence
rates. BC is the sixth tumor with the highest incidence and the eighth one with the highest
mortality.
Despite their high incidence and prevalence, there has been little progress in diagnosis,
prognosis and therapy. Since the prognostic tools currently available have limitations and
acquired changes in specific genes are thought to be significant in the development of bladder
tumours, we needed to improve the research in this field of genetic changes associated with the
BC.
AIM: Characterization of the genomic profile of bladder cancer using the array-Comparative
Genomic Hybridization (aCGH) technique.
Histopathological information from the patients was analyzed and clinical data registered.
This approach allowed us to identify altered chromosomal regions in bladder cancer comparing to normal tissues. In this way, is possible to map fundamental genes related
to disease initiation and progression. The correlation between molecular and clinical-pathological data will be fundamental to identify recognized biomarkers with possible
diagnostic and prognostic interest.
We did not observe a pattern of chromosomal alterations, as, we did not find imbalances in 
more than 20% of patients.
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(A) Genomic changes identified in one of the patients of the present study:
(B) Ideogram representative of all genomic changes identified:
chromosomes with more 
frequent copy number gains
chromosomes with more 
frequent copy number losses
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